Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions
Brief summary
Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about: * The safety of MK-1045 and how well people tolerate it. * The highest dose of MK-1045 that is well tolerated. * How well MK-1045 works to treat relapsed or refractory B-NHL.
Interventions
DRUGMK-1045
IV infusion
Sponsors
MSD R&D (China) Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Inclusion/
Exclusion criteria
Inclusion Criteria Inclusion Criteria include, but are not limited to: * Has relapsed or refractory B-cell Non-Hodgkin's lymphoma (B-NHL) with disease history meeting the following World Health Organization (WHO) diagnostic subtypes of B-NHL that are CD19-positive in pathologic immunohistochemistry test: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) (Grade I to III), marginal zone lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, and transformed large B-cell lymphoma (During the dose-escalation phase, participants, excluding those treated with Chimeric antigen receptor T-cell (CAR-T) who cannot provide proof of pathologic immunohistochemistry CD19 positivity but have previous proof of CD20 positivity may be considered for enrollment after communication with the sponsor) * Relapse is defined as the occurrence of progressive disease (PD) after complete response (CR) or partial response (PR) has been achieved after adequate treatment. Note: For DLBCL participants, relapse must occur after participants undergoing at least two lines of therapy; for other participants, they must undergo at least one line of therapy. * Refractory is defined as a situation that there is no standard of care available or that it is not applicable to use standard of care at this stage, including: Participants who are unresponsive to standard of care (e.g., monotherapy or combination therapy containing anti-CD20 monoclonal antibody) and whose best response to standard therapy is PD or stable disease (SD); Participants who are not eligible for autologous hematopoietic stem cell transplantation (ASCT) and have relapsed PD after receiving ASCT; Participants who have failed on chimeric antigen receptor T cell (CAR-T) immunotherapy, but the first dose of the study intervention must be at least 3 months after discontinuation of CAR-T therapy, and CD19 positive expression is still present in tumor tissue. * Has at least one evaluable tumor lesion per the Lugano 2014 criteria, i.e., a lymph node lesion \> 15 mm in long diameter or an extranodal lesion \> 10 mm in long diameter according to computed tomography (CT) cross-sectional imaging or magnetic resonance imaging (MRI) * Has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2 and an estimated survival time of more than 3 months * Has essentially normal: bone marrow function; coagulation function; liver function; kidney function; lung function; and heart function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants who Experience a Dose-limiting Toxicity (DLT) | Up to ~28 Days | DLT are any of the following drug related (DR) investigator-assessed adverse events: Grade 4 neutropenia that does not recover to Grade ≤ 2 after more than 5 days of supportive care including granulocyte colony-stimulating factor (G-CSF), or ≥ Grade 3 febrile neutropenia; Grade 4 platelet (PLT) decreased, or Grade 3 PLT decreased with bleeding; Grade 4 anemia. Grade 4 non-hematologic toxicity; Grade 3 non-hematologic toxicity that does not recover to Grade ≤ 2 within 3 days after best supportive care (excluding simple laboratory abnormalities without clinical significance as assessed by the investigator). Participants with ≥ Grade 3 tumor lysis syndrome who recover to ≤ Grade 2 within 14 days after optimal supportive therapy will be excluded from the definition of DLT. A DLT was also any other toxic reactions requiring permanent discontinuation of the study intervention. |
| Number of Participants who Experience an Adverse Event (AE) | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. The number of participants who experience an AE will be reported. |
| Number of Participants who Experience a Serious Adverse Events (SAE) | Up to ~15 months | An SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the participant receives the intervention, and congenital abnormalities or birth defects. The number of participants who experience a SAE will be reported. |
| Number of Participants who Experience a Drug-related Adverse Event (DRAE) | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A DRAE is defined as an AE definitely related, probably related, or possibly related to the study intervention. The number of participants who have experienced a DRAE will be reported. |
| Number of Participants who Experience an AE of Grade 3 or higher | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. AEs are graded on a scale from 1-5 with 1=Mild, 2=Moderate, 3=Severe or medically significant but not immediately life-threatening, 4= Life threatening consequences, and 5=Death due to AE. The number of participants who experience an AE of grade 3 or above will be presented. |
| Number of Participants who Experience an AE for Each Severity Grade from 1-5 | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. AEs are graded on a scale from 1-5 with 1=Mild, 2=Moderate, 3=Severe or medically significant but not immediately life-threatening, 4= Life threatening consequences, and 5=Death due to AE. The number of participants who experience an AE in each category of AEs from 1-5 will be presented. |
| Number of Participants who Experience a SAE or Serious Drug-related AE | Up to ~15 months | An SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the participant receives the study intervention, and congenital abnormalities or birth defects. A drug related SAE is defined as an SAE definitely related, probably related, or possibly related to the study intervention. The number of participants who experience a SAE or a serious drug-related AE will be reported. |
| Number of Participants who Experience a Dose Modification Due to an AE or DRAE | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who experience a dose modification due to an AE or DRAE will be presented. |
| Number of Participants who Withdraw from the Study due to an AE or DRAE | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who discontinue the study due to an AE will be presented. |
| Number of Participants who Died due to an AE or DRAE | Up to ~15 months | An AE is defined as any untoward medical event that occurs after a participant receives the study intervention, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the study intervention. A drug related AE includes AEs definitely related, probably related, and possibly related to the study intervention. The number of participants who died due to an AE or DRAE will be presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the Tmax of MK-1045 in plasma. |
| Terminal Elimination Half-life (T1/2) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the t1/2 of MK-1045 in plasma. |
| Clearance (CL) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the CL of MK-1045 in plasma. |
| Concentration at the End of Dosing Interval (Ctrough) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the Ctrough of MK-1045 in plasma. |
| Area Under the Concentration-time Curve from Time 0 to the Dosing Interval (168 Hours) at Steady State (AUC0-tau) of MK-1045 | Pre-dose and at designated time points post-dose up to 168 hours | Blood samples will be collected to determine the AUC0-tau of MK-1045 in plasma. |
| Accumulatio Ratio Based on Cmax (RAC-Cmax) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the RAC\_Cmax of MK-1045 in plasma. |
| Accumulation Ratio Based on AUC0-tau (RAC_AUC0-tau) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the RAC-AUC0-tau of MK-1045 in plasma. |
| Steady State Clearance (CLss) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the CLss of MK-1045 in plasma. |
| Steady State Apparent Volume of Distribution (Vss) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the Vss of MK-1045. |
| Mean Number of B Cells in Peripheral Blood After Administration of MK-1045 | Baseline and up to 12 months | Blood samples will be collected to determine the mean number of B cells in peripheral blood after treatment with MK-1045. |
| Mean Number of T cells in Peripheral Blood After Administration of MK-1045 | Baseline and up to 12 months | Blood samples will be collected to determine the mean number of T cells in peripheral blood after treatment with MK-1045. |
| Mean Level of T Cell Activation After Administration with MK-1045 | Baseline and up to 12 months | Blood samples will be collected to determine the mean T cell activation after treatment with MK-1045. |
| Mean Level of T Cell Proliferation After Administration of MK-1045 | Baseline and up to 12 months | Blood samples will be collected to determine the mean level of T cell proliferation after treatment with MK-1045. |
| Mean Level of Cytokines in Peripheral Blood After Administration of MK-1045 | Baseline up to 12 months | Blood samples will be collected to determine the mean level of cytokines after treatment with MK-1045. |
| Objective Response Rate (ORR) | Up to 15 months | ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants who experience CR or PR will be presented. |
| Percentage of Participants who Develop Anti-drug Antibodies (ADA) to MK-1045 | Baseline and up to 15 months | Blood samples will be collected to determine the percentage of participants with ADAs to MK-1045 after treatment with MK-1045. |
| Duration of Response (DOR) | Up to ~15 months | For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants will be evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR will be presented among participants who demonstrated CR or PR. |
| Complete Response Rate (CRR) | Up to ~15 months | CRR is defined as the percentage of the participants who had complete response (CR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The percentage of participants who experience a CR will be presented. |
| Duration of Complete Response (DCR) | Up to ~15 months | For participants who demonstrate a CR, DCR is defined as the time from the first documented evidence of CR until disease progression or death due to any cause, whichever occurs first. Participants will be evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. DCR for participants with CR will be presented. |
| Progression Free Survival (PFS) | Up to ~15 months | PFS is defined as the time from first dose to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD per Lugano criteria is defined as new or increased adenopathy, splenic volume increase, new or larger non-measured lesions, recurrent previously resolved lesions, new extranodal lesion \>1 cm in any axis, a new node \>1.5 cm in any axis. PFS will be presented. |
| Mean Change in Serum MK-1045 Concentration After Administration | Baseline and up to 12 months | Blood samples will be collected to determine the mean change from baseline in serum concentration of MK-1045. |
| Area Under the Concentration-time Curve (AUC) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the AUC of MK-1045 in plasma. |
| Area Under the Concentration-time Curve from Time 0 to 168 Hours Post Dose (AUC0-168) of MK-1045 | Pre-dose and at designated time points post-dose up to 168 hours | Blood samples will be collected to determine the AUC0-168 of MK-1045 in plasma. |
| Area Under the Concentration-time Curve from Time 0 to Last Quantifiable Concentration Post Dose (AUC0-last) of MK-1045 | Pre-dose and at designated time points post-dose up to 168 hours | Blood samples will be collected to determine the AUC0-last of MK-1045 in plasma. |
| Maximum Concentration (Cmax) of MK-1045 | Pre-dose and at designated time points post-dose up to 12 months | Blood samples will be collected to determine the Cmax of MK-1045 in plasma. |
Countries
China
Contacts
CONTACTToll Free Number
STUDY_DIRECTORMedical Director
Merck Sharp and Dohme LLC
Outcome results
None listed